6/4
04:01 pm
vor
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
5/13
12:16 pm
vor
Vor Biopharma Inc. (NYSE: VOR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
Low
Report
Vor Biopharma Inc. (NYSE: VOR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
5/13
09:19 am
vor
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock, down previously from $15.00.
Medium
Report
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock, down previously from $15.00.
5/10
11:26 am
vor
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Low
Report
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
5/9
04:05 pm
vor
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
Medium
Report
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
5/6
08:00 am
vor
Vor Bio to Participate in Upcoming Investor Conferences
Low
Report
Vor Bio to Participate in Upcoming Investor Conferences
5/3
04:01 pm
vor
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
5/2
04:01 pm
vor
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
Low
Report
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
4/23
01:33 pm
vor
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Low
Report
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
4/1
08:00 am
vor
Vor Bio to Participate in Upcoming Investor Conferences
Medium
Report
Vor Bio to Participate in Upcoming Investor Conferences
3/29
06:40 am
vor
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation [Yahoo! Finance]
Medium
Report
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation [Yahoo! Finance]
3/22
01:46 pm
vor
Vor Biopharma Inc. (NYSE: VOR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
Medium
Report
Vor Biopharma Inc. (NYSE: VOR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.
3/21
10:45 am
vor
Vor Biopharma Inc. (NYSE: VOR) had its price target lowered by analysts at Stifel Nicolaus from $15.00 to $12.00. They now have a "buy" rating on the stock.
Medium
Report
Vor Biopharma Inc. (NYSE: VOR) had its price target lowered by analysts at Stifel Nicolaus from $15.00 to $12.00. They now have a "buy" rating on the stock.
3/21
09:37 am
vor
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $15.00 price target on the stock, down previously from $17.00.
Medium
Report
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $15.00 price target on the stock, down previously from $17.00.
3/21
09:37 am
vor
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Medium
Report
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
3/21
08:06 am
vor
Vor Biopharma Inc. (NYSE: VOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.50 price target on the stock.
Medium
Report
Vor Biopharma Inc. (NYSE: VOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.50 price target on the stock.
3/20
04:05 pm
vor
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Medium
Report
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update